STOCK TITAN

Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Jasper Therapeutics (JSPR) reported a third-quarter 2026 net loss of $144.455 million while advancing its kidney-disease clinical development program. Revenue was $8 million versus none a year earlier, with $7.993 million in associated drug-supply and compound costs. Net loss widened from $18.736 million, including $129.494 million of acquired in-process research and development expense. Cash and cash equivalents reached $135.349 million at September 30.

Jasper completed its all-stock Kira acquisition in July and raised approximately $132 million gross through a convertible preferred stock placement. Enrollment finished in the first Phase 2 IgA nephropathy cohort; Jasper expects interim data in the fourth quarter of 2026. It also began enrollment in another kidney-disease cohort and opened an expansion cohort. A 1-for-30 reverse split took effect in November, leaving approximately 1.1 million common shares outstanding.

Loading...
Loading translation...
13 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointPrivate placement closed July 20, 2026, raising approximately $132.0 million in gross proceeds. 8.7× market cap
  • Moderate pointKira acquisition completed in July 2026 through an all-stock transaction.
  • Moderate pointQuarterly revenue reached $8 million, versus none in third-quarter 2025.
  • Moderate pointNine-month research and development expense fell to $19.276 million from $51.744 million in 2025.
  • Moderate pointTotal liabilities declined to $20.894 million at September 30, from $31.628 million at December 31, 2025.
8 minor points
  • Minor pointCash and cash equivalents rose to $135.349 million at September 30, from $28.692 million at December 31, 2025.
  • Minor pointFirst Phase 2 vensobafusp alfa IgA nephropathy cohort completed enrollment.
  • Minor point. Forward-looking: it has not happened yet and may not happen.IgA nephropathy data expected by Jasper in fourth-quarter 2026, with updated data in first-quarter 2027.
  • Minor pointC3 glomerulopathy/IC-MPGN cohort began enrollment; the first IC-MPGN patient was dosed.
  • Minor point. Forward-looking: it has not happened yet and may not happen.FSGS expansion cohort opened; Jasper expects first patients dosed in first-quarter 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Briquilimab transplant-conditioning study in severe combined immunodeficiency is nearing completion; Jasper expects initial data in fourth-quarter 2026.
  • Minor pointQuarterly research and development expense fell to $8.327 million from $14.391 million a year earlier.
  • Minor pointNine-month general and administrative expense fell to $15.569 million from $16.300 million in 2025.

Negative

  • Major pointQuarterly net loss widened to $144.455 million from $18.736 million; common-stockholder loss per share narrowed to $10.19 from $32.08.
  • Major pointAll-stock Kira consideration and issuance of non-voting convertible preferred stock add dilution exposure.
  • Moderate pointStockholders’ equity became a $140.247 million deficit at September 30, versus $4.151 million equity at December 31, 2025.
  • Moderate pointQuarterly drug-supply and compound costs totaled $7.993 million, versus none a year earlier.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Warrant tender entails approximately $2.8 million cash payment for 283,689 warrants at $9.72 each, post-split. 18% of market cap
3 minor points
  • Minor pointAcquired in-process research and development expense totaled $129.494 million in third-quarter 2026, versus none a year earlier.
  • Minor pointNine-month net loss widened to $148.389 million from $66.700 million; common-stockholder loss per share narrowed to $14.31 from $125.30.
  • Minor pointQuarterly general and administrative expense increased to $6.359 million from $4.775 million a year earlier.

News Explained

Jasper completed its warrant purchase offer, paying approximately $2.8 million in cash for 283,689 tendered warrants; 127,834 warrants remain outstanding.

Key Figures

Cash and cash equivalents: $135.3 million Revenue: $8,000 (in thousands) Research and development expense: $8,327 (in thousands) +4 more
Cash and cash equivalents
$135.3 million
As of September 30, 2026
Revenue
$8,000 (in thousands)
Three months ended September 30, 2026
Research and development expense
$8,327 (in thousands)
Three months ended September 30, 2026
Acquired in-process research and development
$129,494 (in thousands)
Three months ended September 30, 2026
Net loss
$(144,455) (in thousands)
Three months ended September 30, 2026
Interim IgAN data
Expected in the fourth quarter of 2026
Stage 1 of the renal basket study
Private placement gross proceeds
Approximately $132.0 million
Placement closed July 20, 2026

Previous Earnings Reports

1 past event · Latest: Aug 14
Same Type 1 event
  1. Aug 14

    Q2 earnings

    24h Move
    -8.5%

    Completed Kira acquisition and $132 million PIPE financing; KP-104 interim data expected in Q4.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

iga nephropathy, focal segmental glomerulosclerosis, immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplant, +1 more
5 terms
iga nephropathy medical
"evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy"
A kidney disease caused when deposits of the antibody called IgA collect in the tiny filters of the kidney, gradually reducing their ability to clear waste — like grit building up in a water filter. It matters to investors because it creates demand for diagnostics, drugs and long‑term care, drives clinical trial activity and regulatory decisions, and can influence the financial outlook of companies in pharma, biotech, medical devices and health insurance.
focal segmental glomerulosclerosis medical
"patients with focal segmental glomerulosclerosis (FSGS)"
Focal segmental glomerulosclerosis is a chronic kidney disease in which some of the tiny filters in the kidneys (glomeruli) become scarred in parts, reducing the organ’s ability to remove waste and control fluid balance. For investors, it matters because the condition can drive sustained demand for specialized drugs, diagnostic tests, and treatment services, influence healthcare spending and reimbursement dynamics, and affect the commercial prospects of companies developing therapies or diagnostics for rare kidney disorders.
immune complex membranoproliferative glomerulonephritis medical
"immune complex membranoproliferative glomerulonephritis (IC-MPGN)"
A type of kidney inflammation where immune molecules form clumps that stick in and damage the tiny filters in the kidney, causing blood and protein to leak into urine and reducing the organ’s ability to clean the blood. Investors should care because prevalence, treatment options, and clinical trial results for therapies can materially affect healthcare costs, drug company valuations, regulatory decisions, and potential market opportunities in nephrology.
hematopoietic stem cell transplant medical
"SCID patients receiving hematopoietic stem cell transplant"
A hematopoietic stem cell transplant is a medical procedure that replaces a patient’s damaged or diseased blood- and immune‑forming cells with healthy stem cells, acting like a reset button for the body’s blood and immune system. It matters to investors because it signals demand for related drugs, medical devices and hospital services, affects regulatory approval pathways and long‑term patient outcomes, and can materially influence the revenues and valuations of companies in oncology and transplant medicine.
convertible preferred stock financial
"sale of non-voting convertible preferred stock"
Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended September 30, 2026, and provided a corporate update.

“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN),” said Jeet Mahal, President and Chief Executive Officer of Jasper. “In addition, we enrolled the first patient with immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the renal basket study and commenced an expansion cohort in patients with focal segmental glomerulosclerosis (FSGS), with the first patient expected to be dosed in the first quarter of 2027. We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”

Third Quarter 2026 and Recent Highlights

  • Completed enrollment in first cohort of Phase 2 renal basket study evaluating vensobafusp alfa in IgA nephropathy.
    • Jasper expects to report interim IgAN data from Stage 1 of the renal basket study in the fourth quarter of 2026 and updated data in the first quarter of 2027.
  • Announced the opening of an expansion cohort in the renal basket study evaluating vensobafusp alfa in patients with FSGS, with first patients expected to be dosed in first quarter 2027.
  • Commenced patient enrollment in the C3 glomerulopathy (C3G)/IC-MPGN cohort of the renal basket study.
    • First IC-MPGN patient dosed.
    • IC-MPGN is a complement-mediated glomerulonephritis characterized by immune complex deposition, complement activation, and downstream alternative pathway amplification. Given the overlap with C3G in complement biology, IC-MPGN is being evaluated together with C3G in a rare complement-mediated kidney disease cohort
  •  Jasper is completing a Phase 1/2 case control study evaluating briquilimab as a conditioning agent for SCID patients receiving hematopoietic stem cell transplant.
    • The company expects to present initial data from the study in the fourth quarter of 2026.
  • In July 2026, Jasper completed the acquisition of Kira Pharmaceuticals (“Kira”), a Cayman limited company that was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock transaction.
    • Concurrently with the acquisition, Jasper entered into a securities purchase agreement for the sale of non-voting convertible preferred stock (the “Preferred Stock”) in a private placement co-led by Affinity Asset Advisors, LLC and Ikarian Capital LLC with participation from other life science investors. The private placement closed on July 20, 2026 and resulted in gross proceeds of approximately $132.0 million.
  • Announced the appointment of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development.
  • Commenced an offer to purchase any and all of its outstanding warrants that were issued in its underwritten public offering on September 18, 2025. The purchase price was $9.72 in cash per warrant (post-reverse stock split).
    • The Company has been advised that a total of 283,689 Warrants (post-reverse stock split) were properly tendered, which represents an aggregate cash payment of approximately $2.8 million. Following completion of the offer, 127,834 Warrants remain outstanding.
  • In November 2026, Jasper effected a 1-for-30 reverse stock split (“Reverse Split”) of the Company’s common stock. Following the Reverse Split, there were approximately 1.1m shares of common stock issued and outstanding.

Third Quarter Fiscal 2026 Financial Results

  • Cash and cash equivalents as of September 30, 2026, totaled $135.3 million.
  • Research and development expense for the three months ended September 30, 2026, was $8.3 million.
  • General and administrative expense for the three months ended September 30, 2026, was $6.4 million.

About Jasper

Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including vensobafusp alfa, briquilimab, and KP701. Vensobafusp alfa is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant in severe combined immunodeficiencies (SCID), Fanconi anemia, as well as mast cell mediated diseases such as the chronic urticarias. KP701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.

Forward-Looking Statements
Certain statements contained in this press release are or may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate,” “potential,” “projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. Jasper cautions that these statements are based upon the current beliefs and expectations of Jasper’s management and are subject to significant risks, uncertainties and assumptions, including, without limitation, risks related to the market price of Jasper’s common stock relative to the value suggested by the exchange ratio in connection with the merger; unexpected costs, charges or expenses resulting from the merger; potential adverse reactions or changes to business relationships resulting from the completion of the acquisition of Kira; the uncertainties associated with Jasper’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials and the timing of data readouts; risks related to the inability of Jasper to obtain sufficient additional capital to continue to advance product candidates and its preclinical programs; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks associated with the possible failure to realize certain anticipated benefits of the acquisition of Kira, including with respect to future financial and operating results; risks related to the integration of Kira and realization of anticipated benefits from the combination; risks related to the possibility that Jasper’s stockholders may not approve the conversion of the preferred stock and the consequences if such approval is not obtained, including potential obligations to settle preferred stock in cash; Jasper’s ability to maintain the listing of its common stock on the Nasdaq Capital Market; and such additional risks and uncertainties contained in the “Risk Factors” section of Jasper’s Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and other Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that Jasper has subsequently filed or may subsequently file with the SEC. Statements regarding future actions, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of Jasper’s formulations and product candidates and regulatory filings related to the same, financial projections and targets, including, without limitation, cash runway, operating plans, future capital requirements and the sufficiency of existing cash resources, business strategy, plans and objectives for future operations, statements regarding Jasper and its operations and prospects, may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. There is no obligation to update publicly or revise any forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or to changes in Jasper’s expectations, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws.

Contacts:
Alex Gray (investors)
Jasper Therapeutics
650-549-1454 
agray@jaspertx.com

Argot Partners (investors and media)
kira@argotpartners.com


        
JASPER THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
(unaudited)
        
        
 Three Months Ended Nine Months Ended
 September 30, September 30,
  2026   2025   2026   2025 
Revenue$8,000  $—  $8,000  $— 
Costs and Expenses       
Costs of drug supplies and compounds 7,993   —   7,993   — 
Research and development 8,327   14,391   19,276   51,744 
General and administrative 6,359   4,775   15,569   16,300 
Acquired in-process research and development 129,494   —   129,494   — 
Total operating expenses 152,173   19,166   172,332   68,044 
Loss from operations (144,173)  (19,166)  (164,332)  (68,044)
Interest income 999   342   1,245   1,403 
Change in fair value of warrant liability (1,240)  2,099   12,380   2,099 
Other income (expense), net (41)  (2,011)  2,318   (2,158)
Total other income (expense), net (282)  430   15,943   1,344 
Net loss and comprehensive loss$(144,455) $(18,736) $(148,389) $(66,700)
        
        
Net loss per share attributable to common stockholders, basic and diluted$(10.19) $(32.08) $(14.31) $(125.30)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 1,075,259   584,056   1,040,513   532,312 
Net loss per share attributable to non-voting redeemable convertible preferred stockholders, basic and diluted$(13.97) $—  $(13.97) $— 
Weighted-average shares used in computing net loss per share attributable to non-voting redeemable convertible preferred stockholders, basic and diluted 9,555,390   -   9,555,390   - 
        
        
(1) Amounts include non-cash stock based compensation expense as follows (in thousands):
        
 Three Months Ended
September 30,
 Nine Months Ended
September 30,
  2026   2025   2026   2025 
        
Research and development$604  $486  $1,010  $1,600 
General and administrative 615   938   1,396   3,452 
Total$1,219  $1,424  $2,406  $5,052 
        


JASPER THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
    
 September 30, December 31,
Assets 2026   2025 
Current assets:   
Cash and cash equivalents$135,349  $28,692 
Restricted cash, current 417   - 
Accounts receivable 8,000   - 
Prepaid expenses and other current assets 3,508   5,953 
Total current assets 147,274   34,645 
Property and equipment, net 57   102 
Operating lease right-of-use assets 67   502 
Restricted cash, non-current -   417 
Other non-current assets 18   113 
Total assets$147,416  $35,779 
    
Liabilities, Non-voting Redeemable Convertible Preferred Stock and Stockholders’ Equity   
Current liabilities:   
Accounts payable$3,759  $6,220 
Operating lease liabilities 69   1,235 
Accrued expenses and other current liabilities 10,084   5,745 
Total current liabilities 13,912   13,200 
Warrant liability 3,784   16,164 
CVR liability 1,900   - 
Other non-current liabilities 1,298   2,264 
Total liabilities 20,894   31,628 
    
Commitments and contingencies   
Non-voting redeemable convertible preferred stock 263,502   - 
Options for non-voting redeemable convertible preferred stock 3,267   - 
Stockholders’ equity   
Preferred stock -   - 
Common stock 3   3 
Additional paid-in capital 324,809   320,818 
Accumulated deficit (465,059)  (316,670)
Total stockholders’ equity (140,247)  4,151 
Total liabilities, non-voting redeemable convertible preferred stock and stockholders’ equity$147,416  $35,779 
    

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Jasper Therapeutics report Phase 2 IgA nephropathy study results?

Jasper expects interim Stage 1 IgA nephropathy data in the fourth quarter of 2026 and updated data in the first quarter of 2027. Enrollment in the first cohort of the Phase 2 renal basket study evaluating vensobafusp alfa is complete.

What was Jasper Therapeutics’ November 2026 reverse stock split ratio?

Jasper effected a 1-for-30 reverse stock split in November 2026. Following the split, approximately 1.1 million common shares were issued and outstanding.

How many Jasper Therapeutics warrants remain after the tender offer?

Following completion of the offer, 127,834 warrants remain outstanding. A total of 283,689 warrants were properly tendered at $9.72 in cash per warrant, representing an aggregate cash payment of approximately $2.8 million. Warrant counts and the purchase price are post-reverse-split figures.

Keep reading